China Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Report, 2013

This is a professional and depth research report on China Human Immunoglobulin (pH4) for Intravenous Injection industry. This report has firstly introduced Human Immunoglobulin (pH4) for Intravenous Injection definition classification industry chain etc related information. Then introduced Human Immunoglobulin (pH4) for Intravenous Injection manufacturing technology and product specifications, And then summary statistics China major Human Immunoglobulin (pH4) for Intravenous Injection manufacturers 2010-2016 Human Immunoglobulin (pH4) for Intravenous Injection capacity production supply demand shortage and Human Immunoglobulin (pH4) for Intravenous Injection selling price cost gross margin and production value, and also introduced China 25 manufacturers company basic information, 2010-2016 Human Immunoglobulin (pH4) for Intravenous Injection capacity production price cost gross margin production value China market share etc details information. In the end, this report introduced 200K Bottles/year Human Immunoglobulin (pH4) for Intravenous Injection project feasibility analysis and investment return analysis, also give related research conclusions and development trend analysis of China Human Immunoglobulin (pH4) for Intravenous Injection industry. In a word, it was a depth research report on China Human Immunoglobulin (pH4) for Intravenous Injection industry. And thanks to the support and assistance from Human Immunoglobulin (pH4) for Intravenous Injection industry chain related experts and enterprises during Research Team survey and interviews.

Buy a copy of this report @ http://www.reportsnreports.com/reports/217603-2013-china-human-immunoglobulin-ph4-for-intravenous-injection-industry-research-report.html 

Report Details:
Published: January 2013
No. of Pages: 187
Price: Single User License:US$2000         Corporate User License:US$3600
 




Table of Contents
Chapter One Human Immunoglobulin (pH4) for Intravenous Injection Industry Overview    1
1.1 Definition    1
1.2 Classification Application Working Principle    2
1.3 Industry Chain Structure    6
1.4 Market Status and Development Trend    10
1.4.1 Industry Competition Pattern    10
1.4.2 China Market Status    12
1.4.3 China Market Prospect    14
1.5 Policy Analysis    16
Chapter Two Human Immunoglobulin (pH4) for Intravenous Injection Manufacturing Process and Cost Analysis    25
2.1 Product Specifications Analysis    25
2.2 Manufacturing Process Analysis    28
2.3 Cost Structure Analysis    32
2.4 Raw Materials and Equipments Overview    33
2.5 Technical Trend and Difficulties    33
Chapter Three Human Immunoglobulin (pH4) for Intravenous Injection Production Supply Sales Demand Market Status and Forecast    34
3.1 Human Immunoglobulin (pH4) for Intravenous Injection Capacity Production Overview    34
3.2 Human Immunoglobulin (pH4) for Intravenous Injection Guangdong Guizhou Shanghai Sichuan Shandong Henan Etc Regional Production Overview    41
3.3 Human Immunoglobulin (pH4) for Intravenous Injection Capacity Utilization Rate    46
3.4Human Immunoglobulin (pH4) for Intravenous Injection Demand Overview    48
3.5Human Immunoglobulin (pH4) for Intravenous Injection Supply Demand Relationship    50
3.6 Human Immunoglobulin (pH4) for Intravenous Injection Cost Price Production Value Gross Margin    50
3.7 Human Immunoglobulin (pH4) for Intravenous Injection Import Export Consumption    51
Chapter Four Human Immunoglobulin (pH4) for Intravenous Injection Key Manufacturers Analysis    52
4.1 Shanghai Institute of Biological Products Co.,Ltd.    54
4.2 Hualan Bio (002007)    59
4.3 CTBB    64
4.4 Ronsen Pharmaceutical    68
4.5 Shanxi Kangbao Biological Product Co.,Ltd.    75
4.6 Shanghai RAAS (002252)    79
4.7Guizhou Taibang Biological Products Co.,Ltd.    84
4.8 Shenzhen Weiwuguangming Biological Products Co.,Ltd.    90
4.9 Tonrol Pharmaceutical    95
4.10 Banghe Pharmaceutical Co.,Ltd.    101
4.11 Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.    104
4.12 Guangdong Shuanglin Bio-pharmacy Co.,Ltd.    110
4.13 Boya Biological (300294)    115
4.14 Wuhan Institute of Biological Products Co.,Ltd.    120
4.15 PAFC    125
4.16 Shanghai Xinxing Medicine Co.,Ltd.    130
4.17 Wuhan Zhongyuan Ruide Biological Products Co.,Ltd.    135
4.18 Guangdong Weilun Biological Pharmaceutical Co.,Ltd.    140
4.19 Greencross(China)    144
4.20 Guizhou Zhongtai Biological S&T Co.,Ltd.    148
4.21 Lanzhou Institute of Biological Products Co.,Ltd.    150
4.22 Xi’an Huitian Blood Products Co.,Ltd.    154
4.23 Hunan Unisplendour Guhan Nanyue-pharmaceutical Co.,Ltd. (000590)    157
4.25 Haikang Biological Products Co.,Ltd.    162
4.26Walvax Biotechnology Co.,Ltd. (300142) (Hebei Daan)    166
Chapter Five Human Immunoglobulin (pH4) for Intravenous Injection Project Investment Feasibility Analysis    169
5.1 Human Immunoglobulin (pH4) for Intravenous Injection Project SWOT Analysis    169
5.2 200K Bottle/Year Human Immunoglobulin (pH4) for Intravenous Injection (2.5g/Bottle) Project Feasibility Analysis    171
5.2.1 Project Name    171
5.2.2 Project Capacity    171
5.2.3 Project Key Buildings    171
5.2.4 Project Schedule    172
5.2.5 Project Investment Return Analysis    172
Chapter Six Human Immunoglobulin (pH4) for Intravenous Injection Industry Research Conclusions    173 

Contact sales@reportsandreports.com for more details